{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:07:23Z","timestamp":1793398043981,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.sapharm.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T13:09:19Z","timestamp":1701954559000},"page":"236-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-727X","authenticated-orcid":false,"given":"Saharnaz","family":"Nedjat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Eshtiaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0575-7988","authenticated-orcid":false,"given":"Marc","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2023.12.001_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108382","article-title":"The cost of opioid use disorder and the value of aversion","volume":"217","author":"Murphy","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib2","author":"Centers for Disease Control and Prevention (Cdc)"},{"key":"10.1016\/j.sapharm.2023.12.001_bib3","series-title":"Drug Overdose Deaths in the United States, 1999\u20132020. NCHS Data Brief, No 428","author":"Hedegaard","year":"2021"},{"key":"10.1016\/j.sapharm.2023.12.001_bib4","first-page":"Cd002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2","author":"Mattick","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.sapharm.2023.12.001_bib5","series-title":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Mancher M, Leshner AI. Medications For Opioid Use Disorder Save Lives","year":"2019"},{"key":"10.1016\/j.sapharm.2023.12.001_bib6","author":"Park-Lee"},{"key":"10.1016\/j.sapharm.2023.12.001_bib7","first-page":"1573","article-title":"Managing opioid addiction with buprenorphine","volume":"73","author":"Donaher","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.sapharm.2023.12.001_bib8","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJM200510273531724","article-title":"Potential for abuse of buprenorphine in office-based treatment of opioid dependence","volume":"353","author":"Cicero","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2023.12.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108644","article-title":"Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: a systematic review of the neurocognitive effects of buprenorphine and methadone treatment","volume":"135","author":"Mindt","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.sapharm.2023.12.001_bib10","author":"Pharm"},{"key":"10.1016\/j.sapharm.2023.12.001_bib12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.sapharm.2023.12.001_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of Buprenorphine and Naltrexone for opioid use disorder among adolescents and young adults, 2001-2014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.sapharm.2023.12.001_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States","volume":"169","author":"Wu","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107732","article-title":"Prevalence and treatment of opioid use disorders among primary care patients in six health systems","volume":"207","author":"Lapham","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jadohealth.2017.11.033","article-title":"Use of evidence-based medication treatment among Medicaid-enrolled youth with opioid use disorder, 2014\u20132015","volume":"62","author":"Hadland","year":"2018","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.sapharm.2023.12.001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108927","article-title":"Racial inequity in medication treatment for opioid use disorder: exploring potential facilitators and barriers to use","volume":"227","author":"Hollander","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/ADM.0000000000000719","article-title":"Disparities in access to medications for opioid use disorder in the veterans health administration","volume":"15","author":"Finlay","year":"2021","journal-title":"J Addiction Med"},{"key":"10.1016\/j.sapharm.2023.12.001_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amepre.2022.05.006","article-title":"Racial-ethnic disparities of buprenorphine and vivitrol receipt in Medicaid","volume":"63","author":"Dunphy","year":"2022","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.sapharm.2023.12.001_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sapharm.2023.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108589","article-title":"The intersection of race and opioid use disorder treatment: a quantitative analysis","volume":"131","author":"Entress","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.sapharm.2023.12.001_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108512","article-title":"Medications for opioid use disorder among American Indians and Alaska natives: availability and use across a national sample","volume":"220","author":"Krawczyk","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.drugalcdep.2017.06.009","article-title":"Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample","volume":"178","author":"Krawczyk","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugalcdep.2015.12.035","article-title":"Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration","volume":"160","author":"Manhapra","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.sapharm.2023.12.001_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sapharm.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res"},{"key":"10.1016\/j.sapharm.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees","volume":"39","author":"Stein","year":"2018","journal-title":"Subst Abuse"},{"key":"10.1016\/j.sapharm.2023.12.001_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108710","article-title":"Growing racial\/ethnic disparities in buprenorphine distribution in the United States, 2007-2017","volume":"223","author":"Schuler","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.sapharm.2023.12.001_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/00380237.2009.10571347","article-title":"Racial and ethnic composition as a correlate of medication availability within addiction treatment organizations","volume":"42","author":"Knudsen","year":"2009","journal-title":"Social Focus"},{"key":"10.1016\/j.sapharm.2023.12.001_bib32","article-title":"\u201cA Lack of Empathy:\u201d A qualitative study of Black people seeking treatment for opioid use disorder","volume":"4","author":"Khatri","year":"2023","journal-title":"Qualitative Research in Health"},{"key":"10.1016\/j.sapharm.2023.12.001_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0277-9536(99)00338-X","article-title":"The effect of patient race and socio-economic status on physicians' perceptions of patients","volume":"50","author":"Mv","year":"2000","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.sapharm.2023.12.001_bib34","first-page":"56","article-title":"African Americans and their distrust of the health care system: healthcare for diverse populations","volume":"14","author":"Kennedy","year":"2007","journal-title":"J Cult Divers"},{"key":"10.1016\/j.sapharm.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1377\/hlthaff.2020.02510","article-title":"Health care spending and use among Hispanic adults with and without limited English proficiency, 1999-2018","volume":"40","author":"Himmelstein","year":"2021","journal-title":"Health Aff"},{"key":"10.1016\/j.sapharm.2023.12.001_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1533-2500.2010.00421.x","article-title":"Health care provider perceptions of pain treatment in Hispanic patients","volume":"11","author":"Chiauzzi","year":"2011","journal-title":"Pain Pract"},{"key":"10.1016\/j.sapharm.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addbeh.2016.02.030","article-title":"Residential and outpatient treatment completion for substance use disorders in the U.S.: moderation analysis by demographics and drug of choice","volume":"58","author":"Stahler","year":"2016","journal-title":"Addict Behav"},{"key":"10.1016\/j.sapharm.2023.12.001_bib38","article-title":"Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous U.S","author":"Amiri","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.sapharm.2023.12.001_bib39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/ajad.13304","article-title":"Gender differences among persons entering medication treatment for opioid use disorder in the community","volume":"31","author":"Di Paola","year":"2022","journal-title":"Am J Addict"},{"key":"10.1016\/j.sapharm.2023.12.001_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108399","article-title":"Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities","volume":"127","author":"Marsh","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.sapharm.2023.12.001_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108789","article-title":"Deaths associated with opioids, race and ethnicity, and years of potential life lost in Washington State","volume":"139","author":"Amiri","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.sapharm.2023.12.001_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/AIA.0000000000000383","article-title":"Racial inequities in opioid use disorder management: can the anesthesiologist improve outcomes?","volume":"61","author":"Alalade","year":"2023","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.sapharm.2023.12.001_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1108\/S1057-6290(2012)0000014008","article-title":"Two tiers of biomedicalization: methadone, Buprenorphine, and the racial politics of addiction treatment","volume":"14","author":"Hansen","year":"2012","journal-title":"Critical Perspectives on Addiction"},{"key":"10.1016\/j.sapharm.2023.12.001_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1747-597X-3-17","article-title":"State policy influence on the early diffusion of buprenorphine in community treatment programs","volume":"3","author":"Ducharme","year":"2008","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"10.1016\/j.sapharm.2023.12.001_bib45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/AOG.0000000000005227","article-title":"Patient and community factors affecting treatment access for opioid use disorder","volume":"142","author":"Bulgin","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.sapharm.2023.12.001_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamapsychiatry.2022.3673","article-title":"Racial and ethnic disparities in buprenorphine treatment duration in the US","volume":"80","author":"Dong","year":"2023","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.sapharm.2023.12.001_bib47","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/pm\/pny137","article-title":"Race and gender are associated with opioid dose reduction among patients on chronic opioid therapy","volume":"20","author":"Buonora","year":"2019","journal-title":"Pain Med"},{"key":"10.1016\/j.sapharm.2023.12.001_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.14765","article-title":"Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sapharm.2023.12.001_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108533","article-title":"Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation","volume":"133","author":"Johnson","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.sapharm.2023.12.001_bib50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Med Care"},{"key":"10.1016\/j.sapharm.2023.12.001_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109242","article-title":"Effects of Medicaid expansion on alcohol and opioid treatment admissions in U.S. racial\/ethnic groups","volume":"231","author":"Mulia","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"10.1016\/j.sapharm.2023.12.001_bib52","first-page":"S8","article-title":"Challenges in increasing access to buprenorphine treatment for opiate addiction","volume":"13","author":"West","year":"2004","journal-title":"Am J Addict"},{"key":"10.1016\/j.sapharm.2023.12.001_bib53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","article-title":"Addressing racial and ethnic disparities in the use of medications for opioid use disorder","volume":"40","author":"Christou","year":"2021","journal-title":"Health Aff"},{"key":"10.1016\/j.sapharm.2023.12.001_bib54","series-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"10.1016\/j.sapharm.2023.12.001_bib55","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.sapharm.2023.12.001_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174112300493X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174112300493X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:32:38Z","timestamp":1761557558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155174112300493X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S155174112300493X"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2023.12.001","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}